BRPI9811940B8 - vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada. - Google Patents

vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada.

Info

Publication number
BRPI9811940B8
BRPI9811940B8 BRPI9811940A BRPI9811940B8 BR PI9811940 B8 BRPI9811940 B8 BR PI9811940B8 BR PI9811940 A BRPI9811940 A BR PI9811940A BR PI9811940 B8 BRPI9811940 B8 BR PI9811940B8
Authority
BR
Brazil
Prior art keywords
polypeptide
vector
interleukin
modified
producing
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Daniela Novick
Charles Dinarello
Menachem Rubinstein
Soo Hyun Kim
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BRPI9811940A publication Critical patent/BRPI9811940A/pt
Publication of BRPI9811940B1 publication Critical patent/BRPI9811940B1/pt
Publication of BRPI9811940B8 publication Critical patent/BRPI9811940B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
BRPI9811940 1997-08-14 1998-08-13 vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada. BRPI9811940B8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use
PCT/IL1998/000379 WO1999009063A1 (en) 1997-08-14 1998-08-13 Interleukin-18 binding proteins, their preparation and use

Publications (3)

Publication Number Publication Date
BRPI9811940A BRPI9811940A (pt) 2000-09-05
BRPI9811940B1 BRPI9811940B1 (pt) 2011-10-04
BRPI9811940B8 true BRPI9811940B8 (pt) 2021-07-06

Family

ID=27517687

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811940 BRPI9811940B8 (pt) 1997-08-14 1998-08-13 vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada.

Country Status (28)

Country Link
US (4) US6605280B1 (enExample)
EP (1) EP1003781B1 (enExample)
JP (1) JP4272348B2 (enExample)
KR (1) KR100687388B1 (enExample)
CN (1) CN1243021C (enExample)
AR (2) AR013422A1 (enExample)
AT (1) ATE443719T1 (enExample)
AU (1) AU755794B2 (enExample)
BG (1) BG65519B1 (enExample)
BR (1) BRPI9811940B8 (enExample)
CA (1) CA2298855C (enExample)
CY (1) CY1109664T1 (enExample)
CZ (1) CZ300818B6 (enExample)
DE (2) DE69841175D1 (enExample)
DK (1) DK1003781T3 (enExample)
EA (1) EA003675B1 (enExample)
EE (1) EE05538B1 (enExample)
ES (1) ES2149149T3 (enExample)
HU (1) HU226698B1 (enExample)
IL (5) IL121860A0 (enExample)
NO (1) NO327240B1 (enExample)
NZ (1) NZ502392A (enExample)
PL (1) PL206070B1 (enExample)
PT (1) PT1003781E (enExample)
SI (1) SI1003781T1 (enExample)
SK (1) SK287194B6 (enExample)
UA (1) UA75862C2 (enExample)
WO (1) WO1999009063A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
EP1101772B1 (en) * 1999-11-16 2009-01-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
CA2800450A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
NZ520122A (en) * 2000-02-21 2005-04-29 Applied Research Systems Use of IL-18 inhibitors
ATE395075T1 (de) * 2000-05-05 2008-05-15 Serono Lab Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
EP2357002A1 (en) * 2000-10-11 2011-08-17 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
HU229164B1 (en) * 2001-01-29 2013-09-30 Serono Sa Coinsins Lab Use of il-18 inhibitors for the treatment and/or prevention of heart disease
EA009125B1 (ru) * 2001-05-16 2007-10-26 Йеда Рисерч Энд Дивелопмент Ко., Лтд. Применение ингибиторов il-18 для лечения и/или предупреждения заболеваний, характерных для синдрома системной воспалительной реакции
DK1390070T3 (en) * 2001-05-25 2017-04-24 Ares Trading Sa Use of IL-18 inhibitors to treat or prevent CNS damage
BRPI0210579B8 (pt) 2001-06-26 2021-05-25 Amgen Fremont Inc anticorpo e composição farmacêutica
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
PL207303B1 (pl) * 2002-03-22 2010-11-30 Inst Nat Sante Rech Med Zastosowanie inhibitora IL-18 do leczenia i/lub zapobiegania chorobom naczyń obwodowych i zastosowanie wektorów ekspresyjnych
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
JP4563813B2 (ja) * 2002-10-08 2010-10-13 アレス トレーディング ソシエテ アノニム Ｉｌ−１８ｂｐに結合でき、第２サイトカインの活性を阻害するサイトカインの使用
IL152232A0 (en) 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
CN100457901C (zh) * 2003-04-30 2009-02-04 独立行政法人科学技术振兴机构 人抗人白介素-18抗体及其片断和它们的利用方法
ATE549353T1 (de) * 2003-05-13 2012-03-15 Merck Serono Sa Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
AU2004291341B2 (en) * 2003-11-05 2010-08-05 Ares Trading S.A. Process for the purification of IL-18 binding protein
WO2005047478A2 (en) * 2003-11-12 2005-05-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for regulation of tumor necrosis factor-alpha
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
DE602005002829T2 (de) * 2004-03-01 2008-07-10 Ares Trading S.A. Verwendung eines serumfreien zellkulturmediums zur produktion von il-18bp in säugerzellen
US7557084B2 (en) * 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
EP1761552B1 (en) 2004-06-29 2008-09-17 Ares Trading S.A. Process for the purification of il-18 binding protein
ATE557038T1 (de) * 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
EP1888100B1 (en) * 2005-06-03 2011-10-26 Merck Serono SA Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases
SI1891088T1 (sl) * 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
EP2941310A4 (en) * 2013-01-02 2016-08-24 Wilsa Inc METHOD AND DEVICE FOR CONDITIONING LIQUIDS
CN105722858A (zh) 2013-09-05 2016-06-29 Ab2生物股份有限公司 炎性疾病中的il-18结合蛋白(il-18bp)
WO2016139297A1 (en) * 2015-03-05 2016-09-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN120737196A (zh) * 2022-01-28 2025-10-03 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
CA3259975A1 (en) * 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
TW202432591A (zh) 2023-01-06 2024-08-16 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
ES2213209T3 (es) 1996-11-15 2004-08-16 Kennedy Institute Of Rheumatology Supresion de tnfalfa e il-12 en terapia.
AU7624798A (en) 1996-12-06 1998-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
AU734756B2 (en) 1997-03-18 2001-06-21 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
ATE338064T1 (de) 1997-08-01 2006-09-15 Serono Genetics Inst Sa 5' est's für sekretierte proteine, die in verschiedenen geweben exprimiert werden
ATE495257T1 (de) 1997-08-01 2011-01-15 Merck Serono Biodevelopment 5' ests für sekretierte proteine, die in verschiedenen geweben exprimiert werden
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
PL193352B1 (pl) 1998-04-28 2007-02-28 Applied Research Systems Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
US7799541B2 (en) 2010-09-21
EP1003781A1 (en) 2000-05-31
EA003675B1 (ru) 2003-08-28
IL121860A0 (en) 1998-02-22
CN1243021C (zh) 2006-02-22
US20040037829A1 (en) 2004-02-26
CZ2000490A3 (cs) 2000-08-16
IL125463A0 (en) 1999-03-12
JP4272348B2 (ja) 2009-06-03
BRPI9811940B1 (pt) 2011-10-04
CN1267307A (zh) 2000-09-20
DE1003781T1 (de) 2001-01-11
JP2001514876A (ja) 2001-09-18
NO20000700D0 (no) 2000-02-11
DE69841175D1 (de) 2009-11-05
SK287194B6 (sk) 2010-03-08
HK1028773A1 (en) 2001-03-02
US6605280B1 (en) 2003-08-12
KR100687388B1 (ko) 2007-02-26
IL122134A0 (en) 1998-04-05
HU226698B1 (en) 2009-07-28
CZ300818B6 (cs) 2009-08-19
HUP0003533A3 (en) 2003-08-28
US20060154294A1 (en) 2006-07-13
AU755794B2 (en) 2002-12-19
CY1109664T1 (el) 2014-08-13
AR013422A1 (es) 2000-12-27
US8436148B2 (en) 2013-05-07
SI1003781T1 (sl) 2009-12-31
BRPI9811940A (pt) 2000-09-05
WO1999009063A1 (en) 1999-02-25
EA200000216A1 (ru) 2000-08-28
NO20000700L (no) 2000-04-14
ATE443719T1 (de) 2009-10-15
IL134523A0 (en) 2001-04-30
US20100010200A1 (en) 2010-01-14
KR20010022900A (ko) 2001-03-26
ES2149149T3 (es) 2009-12-01
CA2298855C (en) 2014-05-27
PL206070B1 (pl) 2010-06-30
AU8746098A (en) 1999-03-08
PL338647A1 (en) 2000-11-06
HUP0003533A2 (hu) 2001-01-29
EP1003781B1 (en) 2009-09-23
NZ502392A (en) 2002-12-20
PT1003781E (pt) 2009-10-26
SK1762000A3 (en) 2000-09-12
AR062867A2 (es) 2008-12-10
ES2149149T1 (es) 2000-11-01
US7101689B2 (en) 2006-09-05
BG104149A (bg) 2000-08-31
BG65519B1 (bg) 2008-10-31
UA75862C2 (uk) 2006-06-15
CA2298855A1 (en) 1999-02-25
NO327240B1 (no) 2009-05-18
DK1003781T3 (da) 2010-01-25
EE05538B1 (et) 2012-04-16
IL134523A (en) 2011-09-27
EE200000073A (enExample) 2000-10-16

Similar Documents

Publication Publication Date Title
BRPI9811940B8 (pt) vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada.
AU2002360331A1 (en) Egviii endoglucanase and nucleic acids encoding the same
WO2004099370A3 (en) NOVEL BACILLUS mHKcel CELLULASE
BRPI9715219C8 (pt) vetor recombinante de expressão, e célula hospedeira procariótica.
BR9813692B1 (pt) processo para produzir uma vacina da proteìna e2 de pestivìrus recombinante em cultura de células de inseto, e, vacina da subunidade e2.
NO20020276L (no) In vitro seleksjon og valgfri identifikasjon av polypeptider ved bruk av fast-fase-b¶rere
BR9813608B1 (pt) célula hospedeira de bacillus transgênica, e, processo para produzir um polipeptìdeo tendo atividade aminopeptidase.
WO2004043980A3 (en) Bgl6 beta-glucosidase and nucleic acids encoding the same
WO2004048592A3 (en) Bgl7 beta-glucosidase and nucleic acids encoding the same
WO2003027306A3 (en) Bgl3 beta-glucosidase and nucleic acids encoding the same
WO2003052054A3 (en) Bgl5 beta-glucosidase and nucleic acids encoding the same
WO2005001064A3 (en) Polypeptides having alpha-amylase activity and polypeptides encoding same
WO2002062999A8 (en) Proteins and nucleic acids encoding same
WO1999047656A3 (en) Nucleic acid binding proteins
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
WO2004061122A3 (en) Cell proliferation-related polypeptides and uses therefor
BR9801181B1 (pt) gênero alimentìcio fortificado com cálcio, bem como processo para preparação do mesmo.
WO2002046409A3 (en) Proteins and nucleic acids encoding same
DE69841372D1 (de) Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält
NO992916L (no) Fosfodiesterase 8A
FI962268L (fi) Homologinen, rekombinanttinen vasta-aineilmentämisjärjestelmä rottien tai hiirien soluille
WO2000009654A3 (en) Profiling and cataloging expressed protein tags
WO2003050240A3 (en) Expression system
FI971896A7 (fi) BMP-tyyppi II-reseptoria koodaava cDNA
CY1108619T1 (el) Πρωτεϊνη σπονδυλωτων patched-2

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/98, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13.08.2018